Long-term clinical efficacy of sublingual immunotherapy in children with allergic rhinitis.
- Author:
Zhenghua HUANG
;
Ai ZHOU
- Publication Type:Journal Article
- MeSH:
Child;
Child, Preschool;
Female;
Follow-Up Studies;
Humans;
Male;
Prospective Studies;
Rhinitis, Allergic;
therapy;
Sublingual Immunotherapy;
Treatment Outcome
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2014;28(14):1011-1014
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the sustained efficacy of 2-year sublingual immunotherapy (SLIT) and 1 year after 2-year SLIT in children with allergic rhinitis (AR).
METHOD:This study is a randomized, open and prospective trial. One hundred twenty children (between 4 and 11 years old) suffering from AR duo to mite were chosen from November, 2008 to June, 2009 in department of otolaryngology in our hospital divided into two groups: 60 underwent 2-year course of SLIT and one year follow-up combined with 3-year drug therapy as SLIT group; 60 received only drug therapy as control group. The patients were evaluated at three time points (baseline, end of SLIT and 1 year after SLIT discontinuation) regarding symptom scores including total nasal symptom score (TNSS), sneezing, rhinorrhoea, nasal obstruction, nasal itching and total medication scores (TMS) and adverse reaction.
RESULT:(1) At the end of SLIT, the symptom scores excepting sneezing and total medication scores in SLIT group are obviously lower than those in control group (P < 0.01). At 1 year after SLIT discontinuation, all of the score including sneezing (P < 0.05) in SLIT group are lower than those of control group. (2) At the end of SLIT and 1 year after SLIT discontinuation, all of the scores are lower than those at baseline in SLIT group (P < 0.01); the scores were no different in SLIT group between the end of SLIT and 1 year after SLIT discontinuation (P > 0.05). But at the end of SLIT and 1 year after SLIT discontinuation, TMS was higher than it at baseline in control group (P < 0.01). At 1 year after SLIT discontinuation, nasal obstruction score was higher than it at baseline (P < 0.05).
CONCLUSION:SLIT can obviously improve the AR and the efficacy can sustain after 1-year SLIT discontinua tion. Drug increased in 3 years without SLIT.
